NH TherAguix receives FDA Fast Track designation for AGuIX®, its novel radio-enhancer in the treatment of malignant gliomas, and provides an update on its developments and prospects.
NH TherAguix receives FDA Fast Track designation for AGuIX®, its novel radio-enhancer in the treatment of malignant gliomas, and provides an update on its developments and prospects.